ArticleJournal of neurology2025
A population-based study of severe, less common comorbidities in Duchenne muscular dystrophy.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Thrombosis in Neuromuscular Medicine: Current Evidence, Unmet Needs, and Future Directions.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince the increasing longevity and the advent of new therapeutic modalities in Duchenne muscular dystrophy (DMD), comprehensive clinical surveillance is of paramount importance. Our study aimed to examine the occurrence of severe, less common comorbidities among patients with DMD and their impact on life expectancy and overall disease burden.
methodsThis was a retrospective, nationwide study of all male patients with DMD who were followed at a medical clinic in Sweden, born and deceased during the period 1970-2019. Data regarding cause-of-death and comorbidities were retrieved by the medical records and the Cause of death Registry. The assessed variables were defined as 'severe' when depicting comorbidities with potentially serious, life-threatening outcomes.
resultsOf the 129 included patients, approximately 56% presented with at least one severe complication or event, the most common being gastrointestinal complications and life-threatening arrhythmias, with incidence rates of 56.8 and 48.3/10,000 person-years, respectively. Acute kidney injury with an incidence of 16.6/10,000 person-years, was primarily seen within the months preceding death. Vascular events occurred in 10.7% of the patients, mainly cerebrovascular events and venous thromboembolism -including fatal post-traumatic pulmonary embolism-, each with an incidence of 23.5/10,000 person-years. Fracture occurrence, predominantly seen among non-ambulatory patients, had an incidence of 310/10,000 person-years. We further studied cumulative incidences and associations with loss of ambulation and glucocorticoids.
conclusionOur study provides new insights into severe comorbidities in DMD, emphasizing the need for lifelong disease monitoring, especially considering that many complications are subject to prevention and, if detected early, to successful treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.